Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-08-24

Clinical Trial Update: A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression [Phase 3]

View source ↗

Summary

Phase 3 trial investigating olanzapine and fluoxetine for treatment-resistant depression has been terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • olanzapine and fluoxetine combination (olanzapine and fluoxetine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Treatment Resistant Depression | Phase 3 | Status: TERMINATED | Results posted: 2017-08-24